The 2026 Childhood Cancer Report

From diagnosis to research: measuring momentum in the search for cures

Predisposition

At diagnosis, the burning question parents often have is “What caused my child’s cancer?” Not only is childhood cancer rare, but children simply haven’t lived long enough to have collected the risk factors that come with environmental and lifestyle exposures. While researchers do not have a full answer to that question, they do know that up to 18%158 of childhood cancers are driven by predisposition.

Predisposition means that an individual has a genetic mutation that makes them more likely to develop cancer. These mutations can be inherited from a parent but can also form spontaneously without a familial link. Mutations can exist on their own, like in the case of RB1 and retinoblastoma, or be linked to a syndrome, which can come with both cancer predisposition and additional symptoms in the body.

18% of all childhood cancers are driven by predisposition.159

Common Predisposition Types:

  1. Neurofibromatosis-driven cancers:160
    Neurofibromatosis type 1 (NF1) is a condition caused by a mutation in the NF1 gene that leads to the development of tumors that are mostly benign but also have the potential to become malignant.161 NF1 primarily leads to the formation of malignant peripheral nerve sheath tumor (MPNST), but also leads to the increased risk of other tumors, such as gliomas, juvenile myelomonocytic leukemia, or other malignancies.162 Neurofibromatosis type 2 (NF2) is similar to NF1; however, malignant tumor formation is less common than what is observed in NF1. The most common type of tumors developed in NF2 are tumors of the brain and spine, such as ependymoma.

*Neurofibromatosis-driven cancers milestones: Mirdametinib is a small molecule that inhibits an enzyme called MEK, which helps to reduce the size of the tumors formed in NF1. This drug has been approved by the FDA for treating patients with NF1 in 2025.163 Selumetinib, like mirdametinib, is a small molecule inhibitor of MEK that is also used to treat patients with NF1. This drug received FDA approval in 2020 for the treatment of NF1.

  1. Li-Fraumeni Syndrome: Li-Fraumeni Syndrome (LFS) is a cancer predisposition syndrome caused by a mutation in a tumor suppressor gene called TP53. When TP53 is mutated, a large variety of different cancers may form, and patients with this syndrome undergo frequent cancer prevention screening tests.164 LFS is rare, occurring in 1 in 5,000 to 1 in 20,000 people worldwide.165 The types of pediatric cancers that LFS patients are more likely to develop are soft-tissue sarcomas, osteosarcomas, brain tumors, and acute leukemias.166 There are no direct treatment options for patients with LFS, rather enhanced cancer screening protocols are used, along with treatment of the cancer that may have formed from this condition.167
  2. Beckwith-Wiedemann Syndrome: Beckwith-Wiedemann Syndrome (BWS) is a cancer predisposition syndrome that is caused by a mutation in a gene called CDKN1C that leads to the overgrowth of cells and organs and subsequent predisposition to certain types of pediatric cancer, namely Wilms tumor and hepatoblastoma.168,169 BWS, like LFS, does not have any direct treatment options to treat the syndrome, but rather requires enhanced surveillance to help find and treat associated diseases.170

Blue icon of an atom

Types of Predisposition

  • Ataxia-telangiectasia
  • Beckwith-Wiedemann syndrome
  • DICER1 syndrome
  • Familial adenomatous polyposis
  • Hereditary neuroblastoma
  • Hereditary paraganglioma-pheochromocytoma syndrome
  • Juvenile polyposis syndrome
  • Li-Fraumeni syndrome
  • Multiple endocrine neoplasia type 1 (MEN 1)
  • Multiple endocrine neoplasia type 2 (MEN 2)
  • Neurofibromatosis type 1
  • Neurofibromatosis type 2
  • Nevoid basal cell carcinoma syndrome
  • Noonan syndrome
  • Peutz-Jeghers syndrome (PJS)
  • PTEN hamartoma tumor syndrome
  • Retinoblastoma
  • Rhabdoid tumor predisposition syndrome
  • RUNX-1
  • Von Hippel-Lindau (VHL) syndrome
  • WT1-related Wilms tumor (WT) syndromes
  • X-linked lymphoproliferative syndrome

FDA Approvals: Pediatric Predispositions

  • 2020
    Targeted Therapy (Selumetinib)
  • 2025
    Targeted Therapy (Mirdametinib)